Warburg Pincus and Bausch + Lomb in $8.7 Billion Acquisition of Bausch + Lomb by Valeant

Cleary Gottlieb is representing Warburg Pincus and Bausch + Lomb in the all-cash $8.7 billion acquisition of Bausch + Lomb by Valeant Pharmaceuticals International. The deal was announced on May 27. The transaction is expected to close in the third quarter and is subject to customary closing conditions and regulatory approvals.

Bausch + Lomb is a leading global eye health company that is solely focused on protecting, enhancing, and restoring people’s eyesight. Its core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. It globally develops, manufactures and markets one of the most comprehensive product portfolios in the eye health industry, which are available in more than 100 countries. Founded in 1853, the company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide.

Valeant is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.